Alnylam gets $700m Sanofi investment, buys Sirna from Merck
This article was originally published in Scrip
Sanofi's Genzyme business has invested $700m in a 12% stake in Alnylam Pharmaceuticals as part of an expansion of the alliance the two firms formed around Alnylam's lead product, patisiran, in 2012. Separately, Alnylam announced that it will acquire Sirna Therapeutics, a rival RNAi business, from Merck & Co, for $175m plus milestones.
You may also be interested in...
PwC partner Dmitri Drone explained that a deal for an asset with high commercial expectations is best structured with more emphasis on pre-approval than post-approval payments. A post-approval focus on shared risk is more appropriate when an asset is licensed at an earlier stage of development.
Open-label extension Phase II data with RNAi candidate shows patients with transthyretin-mediated amyloidosis polyneuropathy may be regaining sensation and possibly even regenerating nerves.
Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key themes in 2021. Equitable supply and addressing the mental health challenges associated with lockdowns also loom large.